Clinical outcomes of percutaneous radiofrequency ablation for small renal cancer

Ito,Keiichi; Soga,Shigeyoshi; Seguchi,Kenji; Shinchi,Yusuke; Masunaga,Ayako; Tasaki,Shinsuke; Kuroda,Kenji; Sato,Akinori; Asakuma,Junichi; Horiguchi,Akio; Shinmoto,Hiroshi; Kaji,Tatsumi; Asano,Tomohiko

doi:10.3892/ol.2017.6262

Clinical outcomes of percutaneous radiofrequency ablation for small renal cancer

Authors:
- Keiichi Ito
- Shigeyoshi Soga
- Kenji Seguchi
- Yusuke Shinchi
- Ayako Masunaga
- Shinsuke Tasaki
- Kenji Kuroda
- Akinori Sato
- Junichi Asakuma
- Akio Horiguchi
- Hiroshi Shinmoto
- Tatsumi Kaji
- Tomohiko Asano
View Affiliations

Affiliations: Department of Urology, National Defense Medical College, Tokorozawa, Saitama 359‑8513, Japan, Department of Radiology, National Defense Medical College, Tokorozawa, Saitama 359‑8513, Japan
Published online on: May 26, 2017 https://doi.org/10.3892/ol.2017.6262
Pages: 918-924

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Partial nephrectomy is the treatment of choice for small renal cell carcinoma (RCC) from the perspective of cancer management and renal function. However, when patients with RCC are of advanced age, exhibit severe comorbidities, including cardiovascular and pulmonary diseases, or have hereditary RCC, ablative therapies, including radiofrequency ablation (RFA) and cryoablation are useful treatment options. In the present study, the clinical outcomes of percutaneous RFA for treating small RCC were evaluated. Between December 2005 and March 2015, 40 patients (41 renal tumors in total) underwent RFA and a total of 50 sessions of RFA were performed. The average tumor size was 2.5 cm. A total of 18 tumors were exophytic and 23 were parenchymal. Of the 41 tumors, 85.4% were completely ablated by initial RFA and the rate of complete ablation following reablation for residual viable lesions was 95.1%. Local recurrence‑free survival following complete ablation was 84.2% at 3 years. A patient with a 4.7 cm RCC tumor rapidly progressed following four RFA treatments until complete ablation was achieved. The metastasis‑free survival rate following initial RFA was 95.7% at 3 years. The RCC‑specific survival was 100% (mean follow‑up, 38 months). Adverse events occurred in five sessions (10%); however, only 1 patient with arteriovenous fistula required intervention (transarterial embolization). The mean hospital stay following RFA was 3.2 days. The mean decrease in estimated glomerular filtration rate following RFA was 2.7%. The results of the present study indicate that percutaneous RFA was an effective treatment for small RCCs with respect to management of cancer, minimal invasiveness and minimal loss of renal function, particularly in patients for whom surgery would be a high risk and those at increased risk of deterioration of renal function.

View Figures

View References

1	Belldegrun A, Tsui KH, deKernion JB and Smith RB: Efficacy of nephron-sparing surgery for renal cell carcinoma: Analysis based on the new 1997 tumor-node-metastasis staging system. J Clin Oncol. 17:2868–2875. 1999. View Article : Google Scholar : PubMed/NCBI
2	Lam JS, Shvarts O and Pantuck AJ: Changing concepts in the surgical management of renal cell carcinoma. Eur Urol. 45:692–705. 2004. View Article : Google Scholar : PubMed/NCBI
3	Patard JJ, Tazi H, Bensalah K, Rodriguez A, Vincendeau S, Rioux-Leclercq N, Guillé F and Lobel B: The changing evolution of renal tumours: A single center experience over a two-decade period. Eur Urol. 45:490–494. 2004. View Article : Google Scholar : PubMed/NCBI
4	Pignot G, Bigot P, Bernhard JC, Bouliere F, Bessede T, Bensalah K, Salomon L, Mottet N, Bellec L, Soulié M, et al: Nephron-sparing surgery is superior to radical nephrectomy in preserving renal function benefit even when expanding indications beyond the traditional 4-cm cutoff. Urol Oncol. 32:1024–1030. 2014. View Article : Google Scholar : PubMed/NCBI
5	Ito K, Nakashima J, Hanawa Y, Oya M, Ohigashi T, Marumo K and Murai M: The prediction of renal function 6 years after unilateral nephrectomy using preoperative risk factors. J Urol. 171:120–125. 2004. View Article : Google Scholar : PubMed/NCBI
6	Süer E, Burgu B, Gökce Mİ, Türkölmez K, Bedük Y and Baltaci S: Comparison of radical and partial nephrectomy in terms of renal function: A retrospective cohort study. Scand J Urol Nephrol. 45:24–29. 2011. View Article : Google Scholar : PubMed/NCBI
7	Huang WC, Levey AS, Serio AM, Snyder M, Vickers AJ, Raj GV, Scardino PT and Russo P: Chronic kidney disease after nephrectomy in patients with renal cortical tumours: A retrospective cohort study. Lancet Oncol. 7:735–740. 2006. View Article : Google Scholar : PubMed/NCBI
8	Zini L, Perrotte P, Capitanio U, Jeldres C, Shariat SF, Antebi E, Saad F, Patard JJ, Montorsi F and Karakiewicz PI: Radical versus partial nephrectomy: Effect on overall and noncancer mortality. Cancer. 115:1465–1471. 2009. View Article : Google Scholar : PubMed/NCBI
9	Zini L, Patard JJ, Capitanio U, Crepel M, de La Taille A, Tostain J, Ficarra V, Bernhard JC, Ferrière JM, Pfister C, et al: Cancer-specific and non-cancer-related mortality rates in European patients with T1a and T1b renal cell carcinoma. BJU Int. 103:894–898. 2009. View Article : Google Scholar : PubMed/NCBI
10	Lesage K, Joniau S, Fransis K and Poppel HV: Comparison between open and radical nephrectomy for renal tumors: Perioperative outcome and health-related quality of life. Eur Urol. 51:614–620. 2007. View Article : Google Scholar : PubMed/NCBI
11	Berdjis N, Hakenberg OW, Novotny V, Froehner M and Wirth MP: Treating renal cell cancer in the elderly. BJU Int. 97:703–705. 2006. View Article : Google Scholar : PubMed/NCBI
12	Steinbach F, Novick AC, Zincke H, Miller DP, Williams RD, Lund G, Skinner DG, Esrig D, Richie JP, deKernion JB, et al: Treatment of renal cell carcinoma in von Hippel-Lindou disease: A multicenter study. J Urol. 153:1812–1816. 1995. View Article : Google Scholar : PubMed/NCBI
13	Metwalli AR and Linehan WM: Nephron-sparing surgery for multifocal and hereditary renal tumors. Curr Opin Urol. 24:466–473. 2014. View Article : Google Scholar : PubMed/NCBI
14	Ferakis N, Bouropoulos C, Granitsas T, Mylona S and Poulias I: Long-term results after computed-tomography-guided percutaneous radiofrequency ablation for small renal tumors. J Endourol. 24:1909–1913. 2010. View Article : Google Scholar : PubMed/NCBI
15	Tracy CR, Raman JD, Donnally C, Trimmer CK and Cadeddu JA: Durable oncologic outcomes after radiofrequency ablation: Experience from treating 243 small renal masses over 7.5 years. Cancer. 116:3135–3142. 2010. View Article : Google Scholar : PubMed/NCBI
16	Olweny EO, Park SK, Tan YK, Best SL, Trimmer C and Cadeddu JA: Radiofrequency ablation versus partial nephrectomy in patients with solitary clinical T1a renal cell carcinoma: Comparable oncologic outcomes at a minimum of 5 years of follow-up. Eur Urol. 61:1156–1161. 2012. View Article : Google Scholar : PubMed/NCBI
17	Psutka SP, Feldman AS, McDougal WS, McGovern FJ, Mueller P and Gervais DA: Long-term oncologic outcomes after radiofrequency ablation for T1 renal cell carcinoma. Eur Urol. 63:486–492. 2013. View Article : Google Scholar : PubMed/NCBI
18	Ma Y, Bedir S, Cadeddu JA and Gahan JC: Long-term outcomes in healthy adults after radiofrequency ablation of T1a renal tumours. BJU Int. 113:51–55. 2014. View Article : Google Scholar : PubMed/NCBI
19	Wah TM, Irving HC, Gregory W, Cartledge J, Joyce AD and Selby PJ: Radiofrequency ablation (RFA) of renal cell carcinoma (RCC): Experience in 200 tumours. BJU Int. 113:416–428. 2014. View Article : Google Scholar : PubMed/NCBI
20	Ramirez D, Ma YB, Bedir S, Antonelli JA, Cadeddu JA and Gahan JC: Laparoscopic radiofrequency ablation of small renal tumors: Long-term oncologic outcomes. J Endourol. 28:330–334. 2014. View Article : Google Scholar : PubMed/NCBI
21	Kutikov A and Uzzo RG: The R.E.N.A.L. nephrometry score: A comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol. 182:844–853. 2009. View Article : Google Scholar : PubMed/NCBI
22	Koda M, Tokunaga S, Miyoshi K, Kishina M, Fujise Y, Kato J, Matono T, Okamoto K, Murawaki Y and Kakite S: Assessment of ablative margin by unenhanced magnetic resonance imaging after radiofrequency ablation for hepatocellular carcinoma. Eur J Radiol. 81:2730–2736. 2012. View Article : Google Scholar : PubMed/NCBI
23	Schmit GD, Thompson RH, Kurup AN, Weisbrod AJ, Boorjian SA, Carter RE, Geske JR, Callstrom MR and Atwell TD: Usefulness of R.E.N.A.L. nephrometry scoring system for predicting outcomes and complications of percutaneous ablation of 751 renal tumors. J Urol. 189:30–35. 2013. View Article : Google Scholar : PubMed/NCBI
24	Uribe PS, Costabile RA and Peterson AC: Progression of renal tumors after laparoscopic radiofrequency ablation. Urology. 68:968–971. 2006. View Article : Google Scholar : PubMed/NCBI
25	Seki T, Tamai T, Ikeda K, Imamura M, Nishimura A, Yamashiki N, Nakagawa T and Inoue K: Rapid progression of hepatocellular carcinoma after transcatheter arterial chemoembolization and percutaneous radiofrequency ablation in the primary tumour region. Eur J Gastroenterol Hepatol. 13:291–294. 2001. View Article : Google Scholar : PubMed/NCBI
26	Ruzzenente A, Manzoni GD, Molfetta M, Pachera S, Genco B, Donataccio M and Guglielmi A: Rapid progression of hepatocellular carcinoma after radiofrequency ablation. World J Gastroenterol. 10:1137–1140. 2004.PubMed/NCBI
27	Obara K, Matsumoto N, Okamoto M, Kobayashi M, Ikeda H, Takahashi H, Katakura Y, Matsunaga K, Ishii T, Okuse C, et al: Insufficient radiofrequency ablation therapy may induce further malignant transformation of hepatocellular carcinoma. Hepatol Int. 2:116–123. 2008. View Article : Google Scholar : PubMed/NCBI
28	Dong S, Kong J, Kong F, Kong J, Gao J, Ke S, Wang S, Ding X, Sun W and Zheng L: Insufficient radiofrequency ablation promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through Akt and ERK signaling pathways. J Transl Med. 11:2732013. View Article : Google Scholar : PubMed/NCBI
29	Kroeze SG, van Melick HH, Nijkamp MW, Kruse FK, Kruijssen LW, van Diest PJ, Bosch JL and Jans JJ: Incomplete thermal ablation stimulates proliferation of residual renal carcinoma cells in a translational murine model. BJU Int. 110:E281–E286. 2012. View Article : Google Scholar : PubMed/NCBI
30	Hines-Peralta A and Goldberg SN: Review of radiofrequency ablation for renal cell carcinoma. Clin Cancer Res. 10:6328S–6334S. 2004. View Article : Google Scholar : PubMed/NCBI
31	Lian H, Guo H, Zhang G, Yang R, Gan W, Li X, Ji C and Liu J: Single-center comparison of complications in laparoscopic and percutaneous radiofrequency ablation with ultrasound guidance for renal tumors. Urology. 80:119–124. 2012. View Article : Google Scholar : PubMed/NCBI
32	Lucas SM, Stern JM, Adibi M, Zeltser IS, Cadeddu JA and Raj GV: Renal function outcomes in patients treated for renal masses smaller than 4 cm by ablative and extirpative techniques. J Urol. 179:75–80. 2008. View Article : Google Scholar : PubMed/NCBI
33	Hoffmann RT, Jakobs TF, Kubisch CH, Trumm C, Weber C, Siebels M, Helmberger TK and Reiser MF: Renal cell carcinoma in patients with a solitary kidney after nephrectomy treated with radiofrequency ablation: Mid term results. Eur J Radiol. 73:652–656. 2010. View Article : Google Scholar : PubMed/NCBI
34	Raman JD, Raj GV, Lucas SM, Williams SK, Lauer EM, Ahrar K, Matin SF, Leveillee RJ and Cadeddu JA: Renal functional outcomes for tumours in a solitary kidney managed by ablative or extirpative techniques. BJU Int. 105:496–500. 2010. View Article : Google Scholar : PubMed/NCBI